Emerging Technologies in Hemostasis Diagnostics: A Report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group

ABSTRACT

Technology in hemostasis laboratories has evolved enormously during the last 30 years. Although many scientists and clinicians will remember the traditional tilt-tube techniques to screen for coagulation abnormalities and to monitor anticoagulant therapy, the hemostasis laboratory today uses a variety of modern technologies. These include flow cytometry, chromogenic assays, molecular typing (e.g., polymerase chain reaction), immunologic assays (e.g., enzyme-linked immunosorbent assays), functional assays of specific coagulation proteins, and platelet function analyzers. Although these advances in technology have resulted in greater capability, productivity, sensitivity, specificity, and ultimately, improvement in the clinical care of patients, controversies and limitations remain. This article highlights new and emerging technologies in hemostasis and discusses whether they have improved or are likely to improve laboratory diagnostics by specifically addressing the following: (1) Can new technologies help predict likelihood of thrombosis recurrence? (2) Has an understanding of the role of a disintegrin-like and metalloprotease with thrombospondin type 1 motifs (ADAMTS13) in microangiopathy resulted in improved diagnostic methods for this disorder? (3) Does thrombelastography allow better definition of bleeding risk than conventional hemostasis assays, especially in settings of acute hemostatic pathology?

KEYWORDS

Hemostasis - laboratory testing - thrombin generation - thrombophilia - bleeding

REFERENCES

• 1 Prandoni P, Lensing A W, Cogo A et al.. The long-term clinical course of acute deep venous thrombosis.  Ann Intern Med. 1996;  125 1-7
• 2 Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.  Am J Med. 1998;  104 332-338
• 3 Kearon C, Gent M, Hirsh J et al.. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.  N Engl J Med. 1999;  340 901-907
• 4 Kraaijenhagen R A, Haverkamp D, Koopman M M et al.. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism.  Thromb Haemost. 2000;  83 5-9
• 5 Kyrle P A, Minar E, Hisrchl M et al.. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.  N Engl J Med. 2000;  343 457-462
• 6 Kyrle P A, Eichinger S. The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism (review).  Wien Klin Wochenschr. 2003;  115 471-474
• 7 Santamaria M G, Agnelli G, Taliani M R et al.. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.  Thromb Res. 2005;  116 301-306
• 8 Vossen C Y, Walker I D, Svensson P et al.. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia.  Arterioscler Thromb Vasc Biol. 2005;  25 1992-1997
• 9 Kévorkian J-P, Halimi C, Segrestaa J-M et al.. Monitoring of patients with deep-vein thrombosis during and after anticoagulation with D-dimer.  Lancet. 1998;  351 571-572
• 10 Fattorini A, Crippa L, D'Angelo S V et al.. Risk of deep vein thrombosis recurrence: high negative predictive value of D-dimer performed during oral anticoagulation.  Thromb Haemost. 2002;  88 162-163
• 11 Palareti G, Legnani C, Cosmi B et al.. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.  Thromb Haemost. 2002;  87 7-12
• 12 Palareti G, Legnani C, Cosmi B et al.. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.  Circulation. 2003;  108 313-318
• 13 Cosmi B, Legnani C, Cini M et al.. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis.  Thromb Haemost. 2005;  94 969-974
• 14 Baglin T. The measurement and application of thrombin generation.  Br J Haematol. 2005;  130 653-661
• 15 Wielders S, Mukherjee M, Michiels J et al.. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability.  Thromb Haemost. 1997;  77 629-636
• 16 Hemker H C, Giesen P, Al Dieri R et al.. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability.  Pathophysiol Haemost Thromb. 2002;  32 249-253
• 17 Hemker H C, Giesen P LA, Al Dieri R et al.. Calibrated automated thrombin generation measurement in clotting plasma.  Pathophysiol Haemost Thromb. 2003;  33 4-15
• 18 Gerotziafas G T, Despasse F, Busson J et al.. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay.  Thromb J. 2005;  3 16
• 19 Andresen M S, Abilgaard U, Liestol S et al.. The ability of three global plasma assays to recognize thrombophilia.  Thromb Res. 2004;  113 411-417
• 20 Regnault V, Hemker H C, Wahlo D et al.. Phenotyping the haemostatic system by thrombography-potential for the estimation of thrombotic risk.  Thromb Res. 2004;  114 539-545
• 21 Eichinger S, Weltermann A, Phillip K et al.. Prospective evaluation of haemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.  Thromb Haemost. 1999;  82 1232-1236
• 22 Hron G, Kollars M, Binder B R et al.. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation.  JAMA. 2006;  296 397-402
• 23 He S, Antovic A, Blömback M. A simple and rapid laboratory method for determination of haemostasis potential in plasma-II. Modifications for use in routine laboratories and research work.  Thromb Res. 2001;  103 355-361
• 24 Antovic A, Blombäck M, Bremme K et al.. Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance.  J Thromb Haemost. 2003;  1 2531-2535
• 25 Morel-Kopp M-C, Curnow J, Aboud M et al.. Discrepancies between the overall coagulation potential (OCP) assay and international normalised ratio (INR) in warfarin-treated patients.  J Thromb Haemost. 2005;  3(suppl 1) 1376
• 26 Exner T, Joseph J, Low J et al.. A new activated factor X-based clotting method with improved specificity for procoagulant phospholipids.  Blood Coagul Fibrinolysis. 2003;  14 773-779
• 27 Favaloro E J, Soltani S, McDonald J et al.. Laboratory identification of familial thrombophilia: do the pitfalls exceed the benefits? A reassessment of ABO-blood group, gender, age, and other laboratory parameters on the potential influence on a diagnosis of protein c, protein s, and antithrombin deficiency and the potential high risk of a false positive diagnosis.  Lab Hematol. 2005;  11 174-184
• 28 Byrnes J J, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma.  N Engl J Med. 1977;  297 1386-1389
• 29 George J N. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Blood. 2000;  96 1223-1229
• 30 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.  Blood. 1996;  87 4223-4234
• 31 Tsai H M. Physiological cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.  Blood. 1996;  87 4235-4244
• 32 Furlan M, Robles R, Solenthaler M et al.. Deficient activity of von Willebrand factor cleavage-cleaving protease in a patient with thrombotic thrombocytopenic purpura.  Blood. 1997;  89 3097-3103
• 33 Furlan M, Robles R, Solenthaler M et al.. Acquired deficiency of von Willebrand factor cleavage-cleaving protease in a patient with thrombotic thrombocytopenic purpura.  Blood. 1998;  91 2839-2846
• 34 Zheng X, Chung D, Tkayama T K et al.. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.  J Biol Chem. 2001;  276 41059-41063
• 35 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma FVIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
• 36 Lämmle B, Kremer Hovinga J A, Alberio L. Thrombotic thrombocytopenic purpura.  J Thromb Haemost. 2005;  3 1663-1675
• 37 Moake J L. Von Willebrand factor, ADAMTS-13 and thrombotic thrombocytopenic purpura.  Semin Hematol. 2004;  41 4-14
• 38 Meyer D, Obert B, Pietu G et al.. Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease.  J Lab Clin Med. 1980;  95 590-602
• 39 Baillod P, Affolter B, Kurt G H et al.. Multimeric analysis of von Willebrand factor by vertical sodium dodecyl sulphate agarose gel electrophoresis, vacuum blotting technology and sensitive visualisation by alkaline phosphatase complex.  Thromb Res. 1992;  66 745-755
• 40 Veyradier A, Girma J-P. Assays of ADAMTS-13 activity.  Semin Hematol. 2004;  41 41-47
• 41 Allford S L, Harrison P, Lawrie A S et al.. von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura.  Br J Haematol. 2000;  111 1215-1222
• 42 Van der Plas R M, Schiphorst M E, Huizinga E G et al.. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura.  Blood. 1999;  93 3798-3802
• 43 Krizek D M, Rick M E. A rapid method to visualize von Willebrand factor multimers by using agarose electrophoresis, immunolocalization and luminographic detection.  Thromb Res. 2000;  97 457-462
• 44 Obert B, Tout H, Veyradier A et al.. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF.  Thromb Haemost. 1999;  82 1382-1385
• 45 Veyradier A, Obert B, Houllier A et al.. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies.  Blood. 2001;  98 1765-1772
• 46 Gerritsen H E, Turecek P L, Schwartz H P et al.. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP).  Thromb Haemost. 1999;  82 1386-1389
• 47 Aronson D L, Krizek D M, Rick M E. A rapid assay for the vWF protease.  Thromb Haemost. 2001;  85 184-185
• 48 Schneppenheim R, Budde U, Oyen F et al.. von Willebrand cleaving protease and ADAMTS-13 mutations in childhood TTP.  Blood. 2003;  101 1845-1850
• 49 Böhm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS-13).  Ann Hematol. 2002;  81 430-435
• 50 Kostousov V, Fehr J, Bombeli T. Novel, semi-automated, 60-min-assay to determine von Willebrand factor cleaving activity of ADAMTS-13.  Thromb Res. 2006;  118 723-731
• 51 Shenkman B, Budde U, Angerhaus D et al.. D. ADAMTS-13 regulates platelet adhesion under flow.  Thromb Haemost. 2006;  96 160-166
• 52 Kokame K, Nobe Y, Kokubo Y et al.. FRETS-VWF73, a first fluorogenic substrate for ADAMTS-13 assay.  Br J Haematol. 2005;  129 93-100
• 53 Yagi H, Matsumoto M, Iwamoto T et al.. Heightened proteolysis of plasma ADAMTS-13 antigen in patients with thrombotic thrombocytopenic purpura.  Blood. 2004;  104 3946(Abst)
• 54 Wu J-J, Fujikawa K, Lian E C et al.. A rapid enzyme linked assay for ADAMTS-13.  J Thromb Haemost. 2006;  4 129-136
• 55 Rieger M, Ferrari S, Kremer Hovinga J A et al.. Relation between ADAMTS-13 activity and ADAMTS-13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA).  Thromb Haemost. 2006;  95 212-220
• 56 Feys H B, Liu F, Dong N et al.. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences.  J Thromb Haemost. 2006;  4 955-962
• 57 Park Y D, Yoshioka A, Kawa K et al.. Impaired activity of von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation.  Bone Marrow Transplant. 2002;  29 789-794
• 58 Scheiflinger F, Knöbl P, Trattner B et al.. Nonneutralizing IgM and IgG antibodies to von Willebrand factor cleaving protease in a patient with thrombotic thrombocytopenic purpura.  Blood. 2003;  102 3241-3243
• 59 Kremer Hovinga J A, Studt J D, Alberio L et al.. von Willebrand factor-cleaving protease (ADAMTS13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.  Semin Hematol. 2004;  41 75-82
• 60 Remuzzi G. Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura?.  J Thromb Haemost. 2003;  1 632-634
• 61 Tsai H M. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes.  J Thromb Haemost. 2003;  1 625-631
• 62 Loof A H, van Vliet H H, Kappers-Klunne M C. Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura.  Br J Haematol. 2001;  112 1087-1088
• 63 Moore J C, Hayward C P, Warkentin T E et al.. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.  Blood. 2001;  98 1842-1846
• 64 Koh M B, Hunt B J. The management of peri-operative bleeding.  Blood Rev. 2003;  17 179-185
• 65 Levy J H. Massive transfusion coagulopathy.  Semin Hematol. 2006;  43(1, suppl 1) S59-S63
• 66 Rivard G E, Brummel-Ziedins K E, Mann K G et al.. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thromboelastography.  J Thromb Haemost. 2005;  3 2039-2043
• 67 Kolde H J, Strobel G A. Whole blood global haemostasis assay via collagen mediated activation of the haemostasis system.  Ann Hematol. 2003;  82(Suppl 1) S147
• 68 Mallett S V, Cox D JA. Thromboelastography.  Br J Anaesth. 1992;  69 307-313
• 69 Avidan M S, Alcock E L, Da Fonseca J et al.. Comparison of structured use of routine laboratory tests or near patient assessment with clinical judgment in the management of bleeding after cardiac surgery.  Br J Anaesth. 2004;  92 178-186
• 70 Luddington R J. Thrombelastography/thromboelastometry.  Clin Lab Haematol. 2005;  27 81-90
• 71 Piraccini E, Zanzani C, Caporossi E. Intraoperative coagulation monitoring and small bowel transplantation: a way to explore.  Transplant Proc. 2006;  38 823-825
• 72 Gillies B S. Thromboelastography and liver transplantation.  Semin Thromb Hemost. 1995;  21(suppl 4) 45-49
• 73 Kaufmann C R, Dwyer K M, Crews J D et al.. Usefulness of thromboelastography in assessment of trauma patient coagulation.  J Trauma. 1997;  42 716-720
• 74 Vorweg M, Hipp R FJ, Schindler A et al.. Management of coagulation in trauma patients using a new monitoring method.  Anesth Analg. 1996;  82 S54
• 75 Fries D, Innerhofer P, Schobersberger W. Coagulation management in trauma patients.  Curr Opin Anaesthesiol. 2002;  15 217-223
• 76 Savry C, Quinio P, Lefevre F et al.. Manageability and potential for haemostasis monitoring by near-patient modified thromboelastometer (Rotem) in intensive care unit.  Ann Fr Anesth Reanim. 2005;  24 607-616
• 77 Pusateri A E, Park M S. Mechanist implications for the use and monitoring of recombinant activated factor VII in trauma.  Crit Care. 2005;  9(Suppl 5) S15-S24
• 78 Ingerslev J, Christiansen K, Calatzis A et al.. Management and monitoring of recombinant factor VII.  Blood Coagul Fibrinolysis. 2000;  11(suppl 1) S25-S30
• 79 Kawaguchi C, Takahashi Y, Hanesaka Y et al.. The in vitro analysis of the coagulation mechanism of activated factor VII using thromboelastogram.  Thromb Haemost. 2002;  88 768-772
• 80 Shore-Lesserson L, Manspeizer H, DePerio M et al.. Thromboelastography-guided transfusion algorithm reduces transfusion in complex cardiac surgery.  Anesth Analg. 1999;  88 312-319
• 81 Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thromboelastography during cardio-pulmonary by-pass.  Br J Anaesth. 2001;  86 575-578
• 82 Anderson L, Quasim I, Steven M et al.. An audit of red cell and blood product use after institution of thromboelastography in a cardiac intensive care unit.  Br J Haematol. 2003;  121(suppl 1) 80
• 83 Williams G D, Bratton S L, Riley E C et al.. Coagulation tests during cardiopulmonary bypass correlate with blood loss in children undergoing cardiac surgery.  J Cardiothorac Vasc Anesth. 1999;  13 398-404
• 84 Cammerer U, Dietrich W, Rampf T et al.. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery.  Anesth Analg. 2003;  96 51-57
• 85 Wettstein P, Haeberli A, Stutz M et al.. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding.  Anesth Analg. 2004;  99 1564-1569